Cenderitide 

Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research^[1][2][3].

Cenderitide has antiproliferative, anti-fibrotic, and anti-hypertrophic properties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In vivo in normal canines, Cenderitide (10, 50, and 100 ng/kg) is a potent cGMP stimulator that has renal enhancing and cardiac unloading effects, with less reduction of blood pressure^[1][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3745.27

C₁₅₈H₂₆₃N₄₉O₅₀S₃

507289-11-4

Solid

White to off-white

GLSKGCFGLKLDRIGSMSGLGCPSLRDPRPNAPSTSA (Disulfide bridge:Cys6-Cys22)

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. Ichiki T, et al. Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. Int J Cardiol. 2019 Apr 15;281:166-171.  [Content Brief]

  [2]. Wojta J. Cenderitide: a multivalent designer-peptide-agonist of particulate guanylyl cyclase receptors with considerable therapeutic potential in cardiorenal disease states. Eur Heart J Cardiovasc Pharmacother. 2016 Apr;2(2):106-7.  [Content Brief]

  [3]. Lisa C Costello-Boerrigter, et al. Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure. BMC Pharmacol 11 (Suppl 1), P18 (2011).

  [4]. Lisy O, et al. Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol. 2008 Jul 1;52(1):60-8.  [Content Brief]